Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
202 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2014', provides an overview of the H5N1 Infection (Avian Influenza)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 H5N1 Infection (Avian Influenza) Overview 9 Therapeutics Development 10 Pipeline Products for H5N1 Infection (Avian Influenza) - Overview 10 Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis 11 H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies 12 H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes 17 H5N1 Infection (Avian Influenza) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 H5N1 Infection (Avian Influenza) - Products under Development by Companies 21 H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes 25 H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development 26 Akshaya Bio Inc. 26 AlphaVax, Inc. 27 Antigen Express, Inc. 28 Aprogen, Inc. 29 AstraZeneca PLC 30 BioDiem Ltd 31 CEL-SCI Corporation 32 Cocrystal Pharma, Inc. 33 Daiichi Sankyo Company, Limited 34 Emergent BioSolutions Inc. 35 Gemmus Pharma Inc. 36 GlaxoSmithKline plc 37 Green Cross Corporation 38 Hemispherx Biopharma, Inc. 39 iBio, Inc. 40 Immunovaccine, Inc. 41 Inovio Pharmaceuticals, Inc. 42 Johnson & Johnson 43 Kineta, Inc. 44 MacroGenics, Inc. 45 Medicago Inc. 46 Medigen Biotechnology Corporation 47 MedImmune, LLC 48 Microgen Scientific Industrial Company for Immunobiological Medicines 49 Myelo Therapeutics GmbH 50 NanoBio Corporation 51 Nanotherapeutics, Inc. 52 NanoViricides, Inc. 53 Novartis AG 54 OPKO Health, Inc. 55 PaxVax 56 Protein Sciences Corporation 57 REPLICor Inc. 58 SIGA Technologies, Inc. 59 Sirnaomics, Inc. 60 Takeda Pharmaceutical Company Limited 61 TechnoVax, Inc. 62 Vaxart, Inc. 63 Vaxin, Inc. 64 VaxInnate Corporation 65 Vivaldi Biosciences Inc. 66 H5N1 Infection (Avian Influenza) - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Combination Products 68 Assessment by Target 69 Assessment by Mechanism of Action 71 Assessment by Route of Administration 73 Assessment by Molecule Type 75 Drug Profiles 77 A-06 - Drug Profile 77 AE-443p - Drug Profile 78 Alferon LDO - Drug Profile 79 AP-302 - Drug Profile 81 AT-301 - Drug Profile 82 CEL-1000 - Drug Profile 83 DP-C005 - Drug Profile 85 EMER-IT - Drug Profile 86 FBF-001 - Drug Profile 87 flu pandemic (H5N1) vaccine - Drug Profile 88 Flu Vaccine - Drug Profile 89 Gamma-Flu - Drug Profile 90 GelVac - Drug Profile 91 GHB-04L1 - Drug Profile 92 GP-1001 - Drug Profile 93 GP-1002 - Drug Profile 94 GP-1681 - Drug Profile 95 GREFLU/VIE - Drug Profile 97 GSK-1562902A - Drug Profile 98 H5N1 vaccines - Drug Profile 100 HAI-05 - Drug Profile 101 Influ-nRNA - Drug Profile 102 influenza (H5) vaccine - Drug Profile 103 influenza (strain H5N1, H1N1) vaccine - Drug Profile 104 influenza [H5N1] (virus like particle) vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 105 influenza [strain H5N1] vaccine - Drug Profile 107 influenza [strain H5N1] vaccine - Drug Profile 108 influenza A vaccine - Drug Profile 110 influenza vaccine - Drug Profile 111 influenza vaccine - Drug Profile 113 influenza vaccine - Drug Profile 115 influenza vaccine - Drug Profile 116 influezna [H5N1] (virus like particles) vaccine - Drug Profile 117 Innate Immune Adjuvants - Drug Profile 119 INO-3401 - Drug Profile 120 INO-3510 - Drug Profile 121 INO-3605 - Drug Profile 122 INO-3609 - Drug Profile 123 interferon beta-1a - Drug Profile 124 IPS-07 series - Drug Profile 126 KD-295 - Drug Profile 127 KIB-PCI - Drug Profile 128 MEDI-550 - Drug Profile 129 MG-1109 - Drug Profile 131 Monoclonal Antibodies for Infectious Disease - Drug Profile 133 Monoclonal Antibodies to Inhibit H5 HA for H5N1 Infection - Drug Profile 134 Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 135 MVAH-5HA - Drug Profile 136 Myelo-001 - Drug Profile 137 NVINF-1 - Drug Profile 138 NVINF-2 - Drug Profile 140 OrniFlu - Drug Profile 141 pandemic influenza [H5N1/H1N1] vaccine - Drug Profile 142 pandemic influenza [H5N1] vaccine - Drug Profile 143 pandemic influenza vaccine [H5N1] - Drug Profile 144 prepandemic influenza vaccine [H5N1] - Drug Profile 145 PXVX-0103 - Drug Profile 147 REP-9 - Drug Profile 149 rintatolimod - Drug Profile 150 Small Molecule for Influenza Virus - Drug Profile 152 Small Molecules to Inhibit Endonuclease for Flu - Drug Profile 153 STP-702 - Drug Profile 154 TVX-003 - Drug Profile 155 UMN-0501 - Drug Profile 156 VAX-161 - Drug Profile 158 VAX-16101C - Drug Profile 159 VGX-3400X - Drug Profile 160 VX-787 - Drug Profile 162 H5N1 Infection (Avian Influenza) - Recent Pipeline Updates 163 H5N1 Infection (Avian Influenza) - Dormant Projects 184 H5N1 Infection (Avian Influenza) - Discontinued Products 187 H5N1 Infection (Avian Influenza) - Product Development Milestones 188 Featured News & Press Releases 188 Appendix 196 Methodology 196 Coverage 196 Secondary Research 196 Primary Research 196 Expert Panel Validation 196 Contact Us 197 Disclaimer 197
List of Tables Number of Products under Development for H5N1 Infection (Avian Influenza), H2 2014 15 Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H2 2014 16 Number of Products under Development by Companies, H2 2014 18 Number of Products under Development by Companies, H2 2014 (Contd..1) 19 Number of Products under Development by Companies, H2 2014 (Contd..2) 20 Number of Products under Development by Companies, H2 2014 (Contd..3) 21 Number of Products under Investigation by Universities/Institutes, H2 2014 22 Comparative Analysis by Late Stage Development, H2 2014 23 Comparative Analysis by Clinical Stage Development, H2 2014 24 Comparative Analysis by Early Stage Development, H2 2014 25 Products under Development by Companies, H2 2014 26 Products under Development by Companies, H2 2014 (Contd..1) 27 Products under Development by Companies, H2 2014 (Contd..2) 28 Products under Development by Companies, H2 2014 (Contd..3) 29 Products under Investigation by Universities/Institutes, H2 2014 30 H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H2 2014 31 H5N1 Infection (Avian Influenza) - Pipeline by AlphaVax, Inc., H2 2014 32 H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H2 2014 33 H5N1 Infection (Avian Influenza) - Pipeline by Aprogen, Inc., H2 2014 34 H5N1 Infection (Avian Influenza) - Pipeline by AstraZeneca PLC, H2 2014 35 H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H2 2014 36 H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H2 2014 37 H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H2 2014 38 H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 39 H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H2 2014 40 H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H2 2014 41 H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline plc, H2 2014 42 H5N1 Infection (Avian Influenza) - Pipeline by Green Cross Corporation, H2 2014 43 H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H2 2014 44 H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H2 2014 45 H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H2 2014 46 H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 47 H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H2 2014 48 H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H2 2014 49 H5N1 Infection (Avian Influenza) - Pipeline by MacroGenics, Inc., H2 2014 50 H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H2 2014 51 H5N1 Infection (Avian Influenza) - Pipeline by Medigen Biotechnology Corporation, H2 2014 52 H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H2 2014 53 H5N1 Infection (Avian Influenza) - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2014 54 H5N1 Infection (Avian Influenza) - Pipeline by Myelo Therapeutics GmbH, H2 2014 55 H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H2 2014 56 H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H2 2014 57 H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H2 2014 58 H5N1 Infection (Avian Influenza) - Pipeline by Novartis AG, H2 2014 59 H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H2 2014 60 H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, H2 2014 61 H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H2 2014 62 H5N1 Infection (Avian Influenza) - Pipeline by REPLICor Inc., H2 2014 63 H5N1 Infection (Avian Influenza) - Pipeline by SIGA Technologies, Inc., H2 2014 64 H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H2 2014 65 H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 66 H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H2 2014 67 H5N1 Infection (Avian Influenza) - Pipeline by Vaxart, Inc., H2 2014 68 H5N1 Infection (Avian Influenza) - Pipeline by Vaxin, Inc., H2 2014 69 H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H2 2014 70 H5N1 Infection (Avian Influenza) - Pipeline by Vivaldi Biosciences Inc., H2 2014 71 Assessment by Monotherapy Products, H2 2014 72 Assessment by Combination Products, H2 2014 73 Number of Products by Stage and Target, H2 2014 75 Number of Products by Stage and Mechanism of Action, H2 2014 77 Number of Products by Stage and Route of Administration, H2 2014 79 Number of Products by Stage and Molecule Type, H2 2014 81 H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H2 2014 168 H5N1 Infection (Avian Influenza) - Dormant Projects, H2 2014 189 H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H2 2014 191 H5N1 Infection (Avian Influenza) - Discontinued Products, H2 2014 192
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
